Understanding the demand for phenotyped red blood cell units and requests to perform molecular red blood cell typing for Australian patients.

Autor: Hirani R; Australian Red Cross Lifeblood, Sydney NSW, Australia. Electronic address: rhirani@redcrossblood.org.au., Tarafdar S; Australian Red Cross Lifeblood, Sydney NSW, Australia., Mondy P; Australian Red Cross Lifeblood, Sydney NSW, Australia., Powley T; Australian Red Cross Lifeblood, Brisbane QLD, Australia., Daly J; Australian Red Cross Lifeblood, Brisbane QLD, Australia., Irving DO; Australian Red Cross Lifeblood, Sydney NSW, Australia.
Jazyk: angličtina
Zdroj: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2021 Feb; Vol. 60 (1), pp. 102968. Date of Electronic Publication: 2020 Oct 20.
DOI: 10.1016/j.transci.2020.102968
Abstrakt: Background: Australian Red Cross Lifeblood has seen a 50 % increase in demand for phenotyped red blood cell (RBC) units between 2016-2018 and a 30 % increase in demand in 2018 to perform molecular RBC typing on patient samples. Lifeblood conducted a survey to understand transfusion laboratory practices for requesting patient phenotyping and/or molecular RBC typing and for selecting phenotyped RBC units in various patient groups.
Study Design and Methods: An electronic Qualtrics survey form was sent to 296 transfusion laboratories with questions designed to understand the practice of selecting phenotyped RBC units and reasons for requesting extended serology or molecular RBC typing.
Results: 49 (16.6 %) transfusion laboratories provided data. Reasons to request extended phenotyping and/or molecular RBC typing for patients included; chronic transfusion (n = 31 laboratories), sickle cell disease (n = 25), Thalassemia (n = 23), requirement for anti-CD38 or other MAB therapy (n = 23) or Myelodysplasia (n = 22). Forty-seven transfusion laboratories provided responses with reasons for requesting molecular RBC typing which included: predicting phenotype in patients with multiple antibodies (n = 31), prior to administering anti-CD38 or other MAB therapies (n = 29), for pregnancy related transfusions (n = 28) or for confirming the phenotype of recently transfused patients (n = 18).
Conclusion: Transfusion laboratory practices indicated that phenotyped RBC units were selected for patients requiring chronic transfusion support and/or undergoing MAB therapy. Requests for molecular RBC typing occurred for more complex patient requirements where serological investigations were not suitable or possible due to reagent restrictions.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: